Paper No. __
`Filed: February 25, 2016
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`__________________
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`__________________
`LUPIN LTD. and LUPIN PHARMACEUTICALS INC., INNOPHARMA
`LICENSING, INC., INNOPHARMA LICENSING LLC, INNOPHARMA
`INC., INNOPHARMA LLC, MYLAN PHARMACEUTICALS INC., and
`MYLAN INC.
`
`Petitioners,
`
`v.
`
`SENJU PHARMACEUTICAL CO., LTD.,
`Patent Owner.
`__________________
`Case IPR2015-011051
`Patent 8,871,813
`__________________
`PATENT OWNER RESPONSE
`PURSUANT TO 37 C.F.R. § 42.120
`
`
`
`
`
`
`1 Case IPR2016-00090 has been joined with this proceeding.
`
`
`
`

`

`
`
`
`
`
`
`
`
`Patent Owner Response, IPRZOI 5-01 105, US. Patent No. 8,871,813
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Table of Contents
`
`
`
`
`Preliminary Statement
`
`
`
`
`Claim construction
`
`
`
`
`
`
`
`
`
`Level of ordinary skill in the art
`
`
`
`
`
`The ’8l3 patent
`
`
`
`
`
`
`Background of ophthalmic formulations
`
`
`
`
`
`
`
`
`
`
`
`
`
`The combination of Ogawa and Sallmann, in either direction, does not
`
`
`
`
`
`
`
`
`render any claim of the ’813 patent obvious
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`No reason to focus on Ogawa and bromfenac preparations
`
`
`
`
`
`
`
`
`
`
`
`
`
`Design need and market demands would not have led a POSA
`
`
`
`
`
`
`
`
`
`
`
`in the direction that the inventors of the ’8l3 patent took
`
`
`
`
`
`
`
`
`
`
`
`A POSA would not have combined Ogawa and Sallmann
`
`
`
`
`
`
`
`
`
`
`Ogawa and the problem it sought to solve
`
`
`
`
`
`
`
`
`
`Sallmann’s singular purpose does not align with
`
`OgaWa’s
`
`
`
`
`
`1.
`
`2.
`
`
`
`A.
`
`B.
`
`
`
`
`
`
`
`
`
`
`
`
`
`It would not have been obvious to modify Ogawa
`
`
`
`
`
`
`
`
`Example 6 in View of Sallmann Example 2
`
`
`
`
`
`
`
`
`Lupin’s arguments of motivation and expectation
`
`
`
`
`of success ring hollow
`
`
`
`
`
`
`
`
`
`
`
`Sallmann in view of Ogawa: another hindsight-laden
`
`combination
`
`
`
`
`
`1.
`
`
`
`
`
`
`
`
`
`The proposed combination destroys the essential
`
`
`
`
`
`
`
`
`purpose of Sallmann and ignores the blaze marks
`
`
`
`in the art
`
`
`
`
`
`
`
`
`
`
`Lupin’s arguments to modify Sallmann in View of
`
`
`
`
`
`Ogawa are legally insufficient, internally
`
`
`
`
`
`
`
`
`inconsistent, and belied by the very art Lupin cites
`
`
`
`
`
`
`
`

`

`
`
`
`
`
`
`
`
`Patent Owner Response, IPR20I 5-01 I 05, US. Patent No. 8,8 71,813
`
`
`
`
`
`
`
`36
`
`36
`
`36
`
`38
`
`40
`
`
`
`
`
`
`VII. Compelling objective evidence of patentability
`
`
`
`A.
`
`
`
`
`
`
`
`
`Tyloxapo1’s unexpectedly superior chemical stabilizing effect
`
`
`
`1.
`
`
`
`
`2.
`
`3.
`
`
`
`
`4.
`
`
`
`
`
`
`Testing against the closest prior art
`
`
`
`
`
`
`
`
`
`A POSA’s expectation, if anything, of polysorbate
`
`80
`
`
`
`
`
`
`Tyloxapol’s unexpectedly superior stabilizing
`
`effect
`
`
`
`
`
`
`
`Tyloxapol’s unexpectedly better maintenance of
`
`
`preservative efficacy
`
`
`
`
`B.
`
`
`
`
`
`
`Additional compelling objective evidence of patentability
`
`
`
`
`
`
`
`
`VIII. Separate patentability of individual claims
`
`
`
`
`A.
`
`
`B.
`
`
`
`
`
`
`
`
`
`
`
`Separate patentability of claims 4, 6, 12, 16, 18 and 21-22
`
`
`
`
`
`
`
`
`
`Separate patentability of claims 7-12 and 19-22
`
`
`
`IX.
`
`
`
`Conclusion
`
`
`
`
`
`
`
`45
`
`47
`
`52
`
`52
`
`56
`
`59
`
`

`

`
`
`
`
`
`
`
`
`Patent Owner Response, IPR20I5-01 I 05, US. Patent No. 8,871,813
`
`
`
`
`
`TABLE OF AUTHORITIES
`
`
`
`Page(s)
`
`
`
`
`Federal Cases
`
`
`
`
`
`
`Allergan v. Sandoz,
`
`
`
`
`
`
`
`796 F.3d 1293 (Fed. Cir. 2015) ................................................................. ..passim
`
`
`
`
`
`
`In re Antonie,
`
`
`
`
`
`
`
`
`559 F.2d 618 (C.C.P.A. 1977) .................................................................... ..53, 56
`
`
`
`
`
`
`
`
`
`
`Ashlana’ Oil, Inc. v. Delta Resins & Refractories, Inc.,
`
`
`
`
`
`
`
`
`776 F.2d 281 (Fed. Cir. 1985) .......................................................................... ..58
`
`
`
`
`
`
`
`
`
`
`
`Atlas Powder Co. v. E.I. du Pont De Nemours & C0,,
`
`
`
`
`
`
`
`750 F.2d 1569 (Fed. Cir. 1984) ........................... .. ........................................... ..32
`
`
`
`Cadence Pharm. Inc. v. Exela PharmSci Inc.,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`780 F.3d 1364 (Fed. Cir. 2015) ................................................................. ..passim
`
`
`
`
`
`
`
`
`
`
`Catalina Lighting, Inc. v. Lamps Plus, Inc.,
`
`
`
`
`
`
`
`
`295 F.3d 1277 (Fed. Cir. 2002) ........................................................................ ..36
`
`
`
`
`
`
`
`
`
`Depuy Spine, Inc. v. Medtronic Sofamor Danek, Inc.,
`
`
`
`
`
`
`
`
`
`
`
`567 F.3d 1314 (Fed. Cir. 2009) ...................................................... ..11, 12, 27, 32
`
`
`
`
`
`
`
`
`
`Eisai Co. Ltd. v. Dr. Reddy’s Labs, Ltd.,
`
`
`
`
`
`
`
`
`
`533 F.3d 1353, (Fed. Cir. 2008) .6................................................................ ..20, 21
`
`
`
`
`
`
`Galderma Labs. v. Tolmar, Inc.,
`
`
`
`
`
`
`
`
`737 F.3d 731 (Fed. Cir. 2013) .‘........................................................................ ..55
`
`
`
`
`In re Gordon,
`
`
`
`
`
`
`
`733 F.2d 900 (Fed. Cir. 1984) .......................................................................... ..30
`
`
`
`
`
`
`In re Gurley,
`
`
`
`
`
`
`
`
`27 F.3d 551 (Fed. Cir. 1994) ...................................................................... ..14, 24
`
`
`
`
`
`
`
`‘
`In re Huai-Hung Kao,
`
`
`
`
`
`
`
`639 F.3d 1057 (Fed. Cir. 2011) ........................................................................ ..44
`
`
`
`iii
`
`
`
`

`

`Patent Owner Response, IPR2015—01I05, US. Patent No. 8,8 71,813
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Insite Vision Inc., v. Sandoz, Inc.,
`
`
`
`
`
`
`
`
`
`783 F.3d 853 (Fed. Cir. 2015) .................................................................... ..13, 31
`
`
`
`
`
`Institut Pasteur v. Focarino,
`
`
`
`
`
`
`
`
`738 F.3d 1337 (Fed. Cir. 2013) ........................................................................ ..52
`
`
`
`
`
`
`
`Janssen Pharm. NV v. Mylan Pharm., Inc.,
`
`
`
`
`
`
`
`
`
`
`
`
`456 F. Supp. 2d 644 (D.N.J. 2006), afi”dper curiam, 223 Fed.
`
`
`
`
`
`
`
`Appx. 999 (Fed. Cir. 2007) ............................................................................... ..51
`
`A
`KSR Int’! Co. v. Teleflex Inc.,
`
`
`
`
`
`
`
`
`
`
`
`
`550 U.S. 398 (2007) .......................................................................................... ..33
`
`
`
`
`
`
`Microsoft Corp. v. Proxyconn, Inc.,
`
`
`
`
`
`
`
`789 F.3d 1292 (Fed. Cir. 2015) .......................................................................... ..7
`
`
`
`
`
`
`
`
`0rtho—McNeiZ Pharm. Inc. v. Mylan Labs, Inc.,
`
`
`
`
`
`
`
`
`520 F.3d 1358 (Fed. Cir. 2008) ........................................................................ ..36
`
`
`
`
`In re Papesch,
`
`
`
`
`
`
`315 F.2d 381 (C.C.P.A. 1963) .......................................................................... ..44
`
`
`
`
`
`
`
`
`
`
`Par Pharm, Inc. v. TWI Pharms, Inc.,
`
`
`
`
`
`
`
`
`773 F.3d 1186 (Fed. Cir. 2013) ....................................................................... ..57
`
`
`
`
`
`
`
`
`Pfizer Inc. v. Mylan Pharm. Inc.,
`
`
`
`
`
`
`
`
`2014 WL 5388100 (D. Del. 2014) ........................................................ ..23, 26, 31
`
`
`
`
`
`
`In re Shetty,
`
`
`
`
`
`
`
`566 F.2d 81 (C.C.P.A. 1977) ............................................................................ ..57
`
`
`
`
`
`
`Specialty Composites v. Cabot Corp.,
`
`
`
`
`
`
`
`
`845 F.2d 981 (Fed. Cir. 1988) .......................................................................... ..51
`
`
`
`
`
`Syntex LLC v. Apotex Inc.,
`
`
`
`
`
`
`
`
`
`
`
`2006 U.S. Dist. Lexis 36089 (ND. Cal. 2006), afl”d 221 Fed.
`
`
`
`
`
`
`
`
`Appx. 1002 (Fed. Cir. 2007) ....................................................................... ..19, 24
`
`
`
`
`
`
`
`Unigene Labs., Inc. v. Apotex, Inc.,
`
`
`
`
`
`
`
`
`
`
`655 F.3d 1352 (Fed. Cir. 2011) ............................................................ ..20, 21, 53
`
`iv
`
`
`
`

`

`
`
`
`
`
`
`
`
`Patent Owner Response, IPR2015—0II05, US. Patent No. 8,871,813
`
`
`
`
`
`
`In re Wesslau,
`
`
`
`
`
`
`
`
`353 F.2d 238 (C.C.P.A. 1965) .................................................................... ..23, 31
`
`
`Federal Statutes
`
`
`
`
`
`
`
`
`35 U.S.C. § 119 ........................................................................................................ ..7
`
`35 U.S.C. § 316(e) .................................................................. ., ........................... ..1, 6
`
`
`
`
`
`
`
`
`
`
`Other Authorities
`
`
`
`
`
`
`
`
`Apotex Inc., v. Wyeth LLC,
`
`
`
`
`
`
`
`
`
`IPR2014-00115, slip op. (P.T.A.B. Apr. 20, 2015) ................................... ..16, 26
`
`
`
`
`
`
`
`
`
`Sandoz, Inc. v. EKR Therapeutics, LLC,
`
`
`
`
`
`
`
`
`IPR2015-00005, slip op. (P.T.A.B. Apr. 24, 2015) .......................................... ..58
`
`
`
`
`
`
`
`
`Ex parte Whalen et al.,
`
`
`
`
`
`
`
`
`
`
`Appeal 207-4423, slip op. (B.P.A.I. July 23, 2008) ............................. ..53, 54, 56
`
`
`
`
`
`

`

`
`
`
`
`
`
`
`
`Patent Owner Response, IPR2 01 5-01 I 05, US. Patent No. 8,8 71,813
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Patent Owner Senju Pharmaceutical Co., Ltd. et al. (“Senju”) responds to the
`
`
`
`
`
`
`
`
`
`
`
`
`
`Petition filed by Lupin Ltd. and Lupin Pharmaceuticals Inc. (“Lupin”) concerning
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`claims 1-27 of U.S. Patent No. 8,871,813 (“the ’8l3 patent”). The Board instituted
`
`
`
`
`
`
`
`trial on Lupin’s Ground No.
`
`
`
`
`
`
`
`
`
`
`
`1 that claims 1-27 are allegedly obvious over U.S.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Patent No. 5,891,913 to Sallmann et al. (“Sallmann”) (EXl021) in view of U.S.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Patent No. 4,910,225 to Ogawa et al. (“Ogawa”) (EX1010). As discussed below,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Lupin has failed to meet its “burden of proving a proposition of unpatentability by
`
`
`
`
`
`
`
`
`
`
`
`a preponderance of the evidence.” 35 U.S.C. § 3l6(e).
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Indeed, as discussed further below, Lupin has failed to prove that a person of
`
`
`
`
`ordinary skill
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`in the art would have combined Ogawa and Sallmann with any
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`expectation of arriving at the claimed subject matter. Lupin also has failed to prove
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`the existence of all elements of the ’8l3 patent claims in the art of record and has
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`failed to carry the high burden of proving the inherency of several claim elements
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`in the obviousness context. In addition, Lupin either ineffectively assails or simply
`
`
`
`
`
`
`
`
`
`
`
`
`
`ignores significant objective indicia of patentability, which further support the non-
`
`
`
`
`
`
`
`
`
`
`
`
`obviousness of the ’8l3 patent claims. The Board accordingly should uphold the
`
`
`
`
`
`
`
`
`
`
`patentability of claims 1-27 of the ’813 patent.
`
`
`
`
`1.
`
`
`Preliminary Statement
`
`
`
`
`
`
`
`
`
`
`
`
`
`The ’8l3 patent discloses and claims stable aqueous liquid preparations of
`
`
`
`
`
`
`
`
`
`
`
`the non-steroidal anti-inflammatory drug (“NSAID”) bromfenac, marketed as
`
`
`
`

`

`Patent Owner Response, IPR201 5-01 105, U.S. Patent No. 8, 871, 813
`
`Prolensao prescription eye drops for treatment of inflammation and pain in cataract
`
`surgery patients. ‘ These formulations are chemically stable,
`
`lack microbial
`
`contamination, and can be administered safely and effectively for ophthalmic use
`
`at a pH that does not cause eye irritation. (EX1003, 2:24-36; EX2082, 117.)
`
`The inventors successfully formulated these preparations using the non-ionic
`
`surfactant
`
`tyloxapol.
`
`(EX2082,
`
`fiffi16-17.) Tyloxapol unexpectedly chemically
`
`stabilized bromfenac better than did the surfactant polysorbate 80, even at a low
`
`pH known to accelerate bromfenac’s degradation. (M,
`
`‘M 180, 189, 196.)
`
`Tyloxapol also unexpectedly maintained preservative eff1cacy—i.e., prevented
`
`microbial contamination—as compared to polysorbate 80, even when measured
`
`under the stringent European Pharmacopoeia standards. (Id. , 1[200.)
`
`Tyloxapol’s unexpected stabilizing effect translated into significant medical
`
`benefits in Prolensao. Tyloxapol’s stabilization effect permitted formulating
`
`Prolensa° at pH 7-8, down from pH 8.3 in non-prior art Xibrom® and Bromdaym
`
`formulations (EX1049, 4; EX1008, 3; EX1009, 7), a substantial reduction on a
`
`logarithmic scale and closer to the pH of natural tears, which made it more
`
`comfortable to vaticm <EX2116r 1140-)—
`
`’ Lupin’s expert Dr. Lawrence admits that Prolensa® is an embodiment of
`
`certain of the ’813 patent claims. (EXIOOS, W266, 488.)
`
`

`

`
`
`
`
`
`
`
`
`
`Patent‘ Owner Resp0;VLs'e, IPR20J 5-0] 105, U. S. Pa1.‘er7tNo. 8, 8 71, 81 3
`
`
`
`Both the reduction in pH in Prolensa®
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`increased ocular comfort and eliminaterl the burning and stinging associated with
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`all other approved NSA1D eye drops. (Ii) Lowering the pH also improved
`
`
`
`
`
`
`
`
`
`
`
`
`b1'omfenae’s intraoculsr penetration and permitted lowering its concentration to
`
`
`
`
`
`
`
`
`
`
`
`
`0.07%, down from 0.09% in Xibrom® and Bromdayfi, meaning ‘£3331 Prolensa®
`
`
`
`
`
`
`
`
`
`
`
`advantageously puts less drug in Contact with surgically compromised ocular tissue
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`without a reduction in efficacy. (I51, ‘H41; EX2033, 1718.) More than a difference
`
`
`
`in degree,
`
`
`
`
`
`
`
`
`tyloxapoiis unexpectedly superior stabilizing effect constitutes a
`
`
`
`
`
`
`
`
`
`material and substantial difference, producing a more comfortable, norpirritating
`
`
`
`
`
`
`
`
`
`
`and more efficacious formulation embodied in Prolenseg.
`
`
`
`
`
`
`
`
`
`
`
`As a result, Prolensa® has received significant medical. industry aeclairn by
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`numerous leaders in the field of cataract surgery extolling “the benefits of the new
`
`
`
`
`
`
`
`
`
`
`fonnulation.” (EXZI 36, 1155.) Since its April 2013 launch, Prolen.sa® had generated
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`$246.9 million in revenue by August 2015, despite entering a market with at least
`
`
`
`
`
`
`
`
`
`
`
`
`
`six branded drugs and three generic drugs FDA—appr0ved to treat similar
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`indications. (EX2l30, 111117, 147.) In fact, Prolensa® has achieved one of the
`
`
`
`
`
`
`
`
`
`
`
`highest shares of prescriptions and revenue among branded drugs with similar
`
`
`
`
`
`indications. (Id)
`
`Lu
`
`
`
`

`

`Patent Owner Response, 1PR20I5—01105, US. Patent No. 8,871,813
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Moreover, six generic companies, including Lupin, have submitted ANDAS
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`seeking to market exact copies of Prolensa®. (EX2082, 11205.) In fact, Lupin has
`
`
`
`®
`
`
`
`
`
`
`
`
`
`
`
`projected Prolensa ’s sales to exceed $100 million annually, which will occur this
`
`
`
`
`
`
`year. (EX2026, 4; EX2l30,
`
`
`
`
`
`
`
`
`
`'[l73.) Three others, Apotex, Metrics and Paddock,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`initially challenged the ’813 patent and/or related patents in district court (EX2l30,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`111177-80; EX2022; EX2019; EX202l), but all three licensed the ’813 patent and
`
`
`
`
`
`
`
`
`
`
`
`took consent judgments and injunctions, tying their acknowledgement of the ’8l3
`
`
`
`patent’s validity to their generic copies of Prolensa®. (EX2l30, W77-80; EX2027;
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`EX2029; EX2028.)
`
`
`
`Against
`
`
`
`
`
`
`
`
`
`these compelling objective indicia of non-obviousness, Lupin
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`contends that tyloxapol in Sallmann’s Example 2 would have been “swapped” for
`
`
`
`
`
`
`
`
`
`
`
`polysorbate 80 in Ogawa’s Example 6, or alternatively, bromfenac in Ogawa’s
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Example 6 would have been “swapped” for diclofenac in Sallmann’s Example 2.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`(Pet., 37-38.) The Board instituted trial on this sole ground but emphasized that it
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`did so “on the current record.” (Inst. Op. at 10, ll, 13.) As discussed below, upon
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`consideration of the full record, Lupin offers no reason, other than impermissible
`hindsight looking backward from the ’8l3 patent claims, Why a person of ordinary
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`skill in the art (“POSA”) would have chosen Ogawa’s Example 6 or Sallmann’s
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Example 2 and modified either with any reasonable expectation of arriving at any
`
`
`
`
`
`
`
`
`
`
`
`
`of the claimed formulations. Indeed, the evidence establishes that a POSA would
`
`
`
`
`
`

`

`
`
`
`
`
`
`
`A Patent Owner Response, IPR2015—0] 105, US. Patent No. 8,871,813
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`not have been motivated to pursue bromfenac or tyloxapol at all, and would not
`
`
`
`
`
`
`
`
`have found bromfenac and diclofenac, or
`
`
`
`tyloxapol
`
`
`
`
`
`
`and polysorbate 80,
`
`
`
`
`
`
`
`
`
`interchangeable given their vast chemical, physical and functional differences.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Tellingly, Lupin has not proffered a scintilla of evidence for the claims that
`
`
`
`
`
`
`
`
`
`
`
`
`
`specifically require greater than about 90% [or 92%] bromfenac remaining after
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`four weeks at 60° C., and thus Lupin has wholly failed to meet its burden of
`
`
`
`
`
`
`proving these claims obvious.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Lupin and its expert Dr. Jayne Lawrence contend that its “swapping” theory
`
`
`
`
`
`
`
`
`
`
`
`
`
`allegedly solves the problem of a “complex” that bromfenac purportedly forms
`
`
`
`
`
`
`
`
`
`
`with the preservative benzalkonium chloride (“BAC”). Yet Dr. Paul Laskar,
`
`
`
`
`
`
`
`
`
`
`
`
`
`Lupin’s expert in related proceeding IPR20l5-00903, candidly admits that no prior
`
`
`
`art shows that bromfenac actually forms a “complex” with BAC. Consistent with
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`the teachings of the art, given that BAC was known to have significant toxicity to
`
`
`
`
`
`
`
`
`
`
`
`
`
`the eye, a POSA as of 2003 would have pursued non-BAC preservatives or
`
`
`
`
`
`
`
`
`
`
`
`
`unpreserved formulations to entirely eliminate a serious health risk. Proceeding
`
`
`
`contrary to accepted wisdom, the ’8l3 patent’s fonnulations utilize BAC, which
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`alone constitutes strong evidence of non—0bviousness.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Accordingly, and as discussed below, Lupin’s petition fails (i) to prove that
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`a person of ordinary skill in the art would have combined Ogawa and Sallmann
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`with any reasonable expectation of arriving at the claimed subject matter; (ii) to
`
`
`
`

`

`Patent Owner Response, IPR20]5—01I05, US. Patent No. 8,871,813
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`prove the existence of each element of each challenged claim from Ogawa and
`
`
`
`
`
`
`
`
`
`
`
`
`
`Sallmann, including the alleged inherency of various claim elements; and (iii) to
`
`
`
`
`
`
`
`
`
`
`
`rebut the compelling objective indicia of non—obviousness of the claimed subject
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`matter. As result, Lupin has not carried its “burden of proving .
`
`
`. unpatentability
`
`
`
`.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`by a preponderance of the evidence,” 35 U.S.C. § 3l6(e), and the Board should
`
`
`
`
`
`
`
`
`
`
`
`
`
`enter judgment against Lupin and uphold the patentability of the claims.
`
`
`
`
`II.
`
`
`Claim construction
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`All claims of the ’8l3 patent contain the term “stable,” and claims 1-6
`
`
`
`
`
`
`
`
`further contain the phrase “amount sufficient
`
`
`
`
`
`
`
`to stabilize.” Senju and Lupin
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`disputed the meaning of this term and phrase in parallel district court litigation
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`before Chief Judge Simandle of the U.S. District Court for the District of New
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Jersey. On behalf of Senju, Dr. Robert Williams, III. Ph.D., who is an expert in the
`
`
`
`
`
`
`
`
`
`
`
`
`
`field of pharmaceutical formulation and development and who, based on his
`
`
`
`
`
`education and experience,
`
`
`
`
`
`
`
`
`
`
`
`is qualified to provide his opinions in this matter
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`(EX2082, W2-l 1), has submitted a declaration in this proceeding and in the claim
`
`
`
`
`
`construction proceedings before
`
`
`
`
`
`
`
`
`Judge Simandle (EX2l25). Adopting Dr.
`
`
`
`
`
`
`
`Williams’ construction of the elements “stable” and
`
`
`
`
`amount sufficient
`
`
`
`to
`
`
`
`(G
`
`
`
`
`
`
`
`
`
`
`stabilize” (EX2082, W48-52; EX2l25; EX2065, 5-6), Judge Simandle held that
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`“stable” as used in the claims of the ’813 patent means having sufficient resistance
`
`
`
`
`
`
`
`
`
`
`
`
`to degradation (i.e., chemical stability) and having sufficient preservative efficacy
`
`
`
`
`
`

`

`
`
`
`
`
`
`
`
`Patent Owner Response, IPR20I5—0] 105, US. Patent No. 8,871,813
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`to be formulated and maintained for ophthalmic use, and the phrase “amount
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`sufficient to stabilize” as used in the claims of the ’813 patent means an amount
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`sufficient to confer sufficient resistance to degradation (i.e., chemical stability) to
`
`
`
`
`
`
`
`
`
`
`
`be formulated and maintained for ophthalmic use. (EX2082, 1151; EX2065, 5-6.)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Senju submits that the above terms should be construed in this proceeding in the
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`same Way the District Court construed them. Microsofl Corp. v. Proxyconn, Inc.,
`
`
`
`
`
`
`
`789 F.3d 1292, 1298 (Fed. Cir. 2015).
`
`
`
`
`
`
`
`
`
`
`III. Level of ordinary skill in the art
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`A person of ordinary skill in the art of the ’813 patent would have at least a
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`bachelor’s degree in a field such as chemistry, pharmaceutical chemistry or a
`
`
`
`
`
`
`
`
`
`
`
`
`related discipline with 3~5 years of work experience. (EX2082, W46-47.)
`
`
`
`IV.
`
`
`
`
`
`The ’813 patent
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`The application for the ’813 patent was filed on April 25, 2014, and claims
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`priority benefit of the January 21, 2003, filing date of JP 2003-012427 under 35
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`U.S.C. § 119. (EXl003.) The ’8l3 patent has three independent claims (claims 1, 7
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`and 13) and 24 dependent claims, which are separately patentable. The ’813 patent
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`is listed in the FDA’s’ Orange Book, and the parties agree that it covers Prolensa®
`
`
`
`
`
`
`
`
`
`
`ophthalmic bromfenac (0.07%) solution. (EXl005, W266, 488; EX2082, W176,
`
`228.)
`
`
`
`
`
`

`

`
`
`
`
`
`
`
`
`Patent Owner Response, IPR20I5—0]I05, US. Patent No. 8,871,813
`
`
`
`
`V.
`
`
`
`
`
`Background of ophthalmic formulations
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`As of the January 21, 2003 priority date of the ’8l3 patent, drug formulation
`
`
`
`
`
`
`
`
`was a difficult and unpredictable endeavor, and it
`
`
`
`
`
`
`remains so today. The
`
`
`
`
`
`
`
`
`
`
`
`formulation of ophthalmic drugs is particularly complex. Formulating stable
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`ophthalmic dosage forms such as the stable aqueous liquid preparations of the ’813
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`patent is more challenging and critical than with other dosage forms such as tablets
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`or capsules. In addition, the surface area of the eye is extremely small, and the
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`residence time for an eye drop is quite short, which increases the challenge in
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`designing an aqueous dosage form that can pass through the hydrophobic cornea
`
`
`
`
`
`
`
`
`
`
`
`
`
`membrane of the eye to reach the intended site of action.
`
`
`
`
`
`
`Indeed, Dr. Laskar has
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`acknowledged these formulation challenges in his prior sworn testimony in a
`
`patent infringement case involving the ophthalmic product Combigan®. (EX2l35,
`
`
`
`
`
`
`
`
`
`
`
`
`
`989, 1020, 1022.)
`
`
`
`VI.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`The combination of Ogawa and Sallmann, in either direction, does not
`
`
`
`
`
`
`
`
`render any claim of the ’813 patent obvious
`
`
`
`
`A.
`
`
`
`
`
`
`
`
`
`No reason to focus on Ogawa and bromfenac preparations
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Lupin’s central theme is one of “swapping”; that is, swapping tyloxapol in
`
`
`
`
`
`
`
`
`
`
`
`
`Sallmann’s Example 2 for polysorbate 80 in Ogawa’s Example 6, or alternatively,
`
`
`
`
`
`
`
`
`
`
`
`
`
`swapping bromfenac in Ogawa’s Example 6 for diclofenac in Sallmann’s Example
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`2, allegedly would have been obvious. (Pet., 37-38.) The full record shows this
`
`
`
`
`
`

`

`
`
`
`
`
`
`
`
`Patent Owner Response, IPR20I5-01105, US. Patent No. 8,871,813
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`swapping theory is premised on a POSA having had a reason to focus on
`
`
`
`
`
`
`
`
`
`bromfenac formulations. There was none, absent hindsight.
`
`
`
`
`
`
`By January 21, 2003,
`
`
`
`
`
`
`
`
`
`there were a number of FDA-approved aqueous
`
`
`
`
`
`
`ophthalmic formulations containing NSAIDS,
`
`
`
`
`
`
`including diclofenac (Voltaren®),
`
`
`
`
`
`
`
`
`
`ketorolac (Acular®), flurbiprofen (Ocufen®), and suprofen (Profenal®). (Id., 6-7;
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`EXZO82, W67-68.) A POSA therefore would have had no reason or need to focus,
`
`for
`
`
`further development, on bromfenac to the exclusion of other NSAIDS.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`(EX2082, W67-68.) Indeed, Lupin admits there was no such reason, stating “[t]o
`
`
`
`
`the extent
`
`
`
`
`
`
`
`
`
`
`
`
`there was even any need for the claimed bromfenac ophthalmic
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`formulations claimed in the ’813 patent, it would have been met by the disclosures
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`of the ’225 patent and Hara.” (Pet., 58 (emphasis added).) In fact, Ogawa states
`
`
`
`
`
`
`
`
`
`
`
`that its bromfenac formulations displayed remarkably enhanced stability (EX10l0,
`
`
`
`
`
`
`
`
`
`
`
`
`8:46-9:3), and Dr. Laskar acknowledged that Ogawa satisfied bromfenac’s stability
`
`
`
`
`
`problem. (EX2114, 115:2-116-4.)
`
`
`
`
`
`
`
`
`
`
`
`
`
`Moreover, contrary to Lupin’s position, neither Hara nor Yanni supports a
`
`
`
`
`
`
`
`
`
`
`
`
`preference for bromfenac over diclofenac. (EX2082, 111169-72.) Hara teaches that
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`(1) both have “superior” anti-inflammatory action (EXl006, 2, 3), (2) both treat
`
`
`
`
`
`
`
`
`
`
`
`
`
`postoperativeinflammation of the eye (id.), (3) diclofenac could treat anterior
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`uveitis, while bromfenac was expressly not approved for this indication (id.), and
`
`
`
`
`
`
`
`
`
`
`
`
`(4) no toxicity issues were noted for commercialized diclofenac, while bromfenac
`
`
`
`
`
`

`

`
`
`
`
`
`
`
`Patent Owner Response, IPR20]5-0] I 05, US. Patent No. 8,871,813
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`had serious liver disorders and even fatalities (z'd.), which prompted the FDA to
`
`
`
`
`
`
`
`
`
`
`
`
`
`pull bromfenac’s oral form, Duract®, from the market. (EXZO32, 1.) Hara thus
`
`
`
`
`
`
`
`
`
`certainly does not endorse bromfenac over diclofenac. (EX2082, 1170.)
`
`
`
`
`
`
`
`
`
`
`
`
`The same applies to Yanni, which actually disparages bromfenac, preferring
`
`
`
`
`
`
`
`
`
`
`
`
`
`esters and amides, like nepafenac. (EXl007, 1:54-59, 4:84-52; EX2082, 111171-72.)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Focusing on a single in vitro result from Table 1 of Yanni (EXl005, 1177), Dr.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Lawrence ignores important ex vivo and in vivo data (EX2082, 1171-72), which do
`
`not show superiority of bromfenac over diclofenac and in fact show superiority of
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`other compounds. (Id.; EXIOO7, Table 1.)
`
`
`
`B.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Design need and market demands would not have led a POSA in
`
`
`
`
`
`
`
`
`
`
`the direction that the inventors of the ’813 patent took
`
`
`
`
`
`
`
`
`
`
`
`Lupin’s proffered motivation to substitute polysorbate 80 with tyloxapol is
`
`to prevent the alleged formation of an insoluble complex between an acidic
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`NSAID and BAC. (Pet., 8-9.) Dr. Laskar admits, however, that he has no evidence
`
`
`
`
`
`
`
`
`
`
`
`
`
`that any such complex actually forms between bromfenac and BAC. (EX2ll4,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`45:18-46:4.) Even if such a precipitate did form, which Lupin has not established,
`
`
`
`
`
`
`
`
`
`
`
`
`
`a POSA would not have used tyloxapol to address this issue.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`BAC was known to have significant toxicity to the eye. (EX2082, 111175-
`
`
`
`
`76.) In fact,
`
`
`
`
`
`
`
`
`
`
`
`
`in Allergan v. Sandoz, 796 F.3d 1293, 1305 (Fed. Cir. 2015), the
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`defendant’s expert referred to BAC as a “natural born killer” that was “from
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Satan.” Dr. Laskar also characterized BAC as a “killer,” known to cause adverse
`
`
`
`10
`
`
`
`

`

`
`
`
`
`
`
`
`
`Patent Owner Response, IPR20I5-01105, US. Patent No. 8,871,813
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`reactions in vitro and in vivo. (EX2114, 78:13-25, 79:13-23.) A POSA objectively
`
`
`
`
`
`
`
`
`
`
`
`
`
`viewing this alleged precipitation issue would have sought to eliminate BAC,
`
`
`
`
`
`
`
`
`
`
`
`
`
`thereby eliminating its harmful effects and avoiding the precipitation issue entirely,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`rather than only attempting to reduce it to some extent by adding a surfactant.
`
`
`
`(EX2082,
`
`
`
`
`
`
`1173.) By January 2003,
`
`
`
`the
`
`
`
`art
`
`
`
`
`
`taught using preservative-free
`
`
`
`
`
`
`
`
`
`
`
`
`formulations and well-tolerated preservatives in place of BAC (EX2082, 1174;
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`EX21l6, 111144-46.) Depuy Spine, Inc. v. Medtronic Sofamor Danek, Inc., 567 F.3d
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`1314, 1326 (Fed. Cir. 2009) (strong inference of non-obviousness when the prior
`
`
`
`
`
`
`
`
`
`
`art undermines very reason offered for combining references).
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Indeed by 2003, market demands sought to eliminate the highly toxic BAC
`
`
`
`
`
`
`
`
`
`
`from ophthalmic formulations. The art urged that “[i]t
`
`
`
`
`is
`
`
`
`.
`
`
`
`.
`
`
`
`. of striking
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`importance to become aware of preservative toxicity in order to develop in the
`
`
`
`
`
`
`
`
`
`
`
`
`near future many more unpreserved drugs.” (EX2064, 115, emphasis added;
`
`
`
`
`
`
`
`
`
`
`
`EX2082, 1176-77.) The art taught a preservative—free formulation of Fu’s ketorolac
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`“may be a better as a postoperative ocular analgesic” than preserved ketorolac.
`
`
`
`(EX2090,
`
`
`
`
`abstract; EX2ll6,
`
`
`
`
`
`1143.) By November
`
`
`
`
`
`1997, Acular® PF—a
`
`
`
`preservative-free
`
`
`
`ketorolac
`
`
`
`ophthalmic
`
`
`
`
`
`solution—received FDA approval.
`
`
`
`
`
`
`
`(EX2061, 1; EX21 16, 1129.)
`
`
`
`
`
`
`
`
`
`
`
`
`The art also taught using better-tolerated preservatives in place of BAC. By
`
`
`
`
`
`
`
`
`
`
`
`2001, published clinical studies demonstrated that the preservative “stabilized
`
`
`
`ll
`
`
`
`

`

`
`
`
`
`
`
`
`Patent Owner Response, IPR2015-01105, US. Patent No. 8,871,813
`
`
`
`
`
`
`
`
`
`
`
`oxychloro complex” (“SOC”) could replace BAC in brimonidine ophthalmic
`
`
`
`
`
`
`
`
`
`
`
`
`
`formulations. By March 2001, brimonidine-SOC was approved as Alphagan® P,
`
`
`
`
`
`
`
`
`
`
`
`
`
`with a superior comfort and reduced ocular allergy profile as compared to
`
`
`
`
`brimonidine-BAC. (EX2092; EX2116, 1144.)
`
`
`
`
`
`
`
`
`
`
`
`Other replacement options for BAC included the preservative lauralkonium
`
`
`
`
`
`
`
`
`
`
`
`
`
`chloride (“LAC”), which Dr. Laskar admittedly used previously to avoid the
`
`
`
`
`
`
`
`
`
`
`
`
`
`interaction of an acidic drug and BAC. IPR2015-00903, EX1003, 11104; (EX21 14,
`
`
`
`
`
`
`
`
`
`
`
`
`33:4-34:1; EX2082, 1179; EX1027, 3:28-4:2, 6:11-7:10). Dr. Lawrence admits that
`
`
`
`
`
`
`
`
`
`
`
`
`
`Desai also teaches the use of a different polymeric quaternary ammonium
`
`
`
`
`
`
`
`
`
`
`
`
`
`preservative compound, POLYQUAD®, as the solution to the interaction problem.
`
`
`
`
`
`
`
`
`
`
`
`
`
`(EX1012, 1:27-2:31; EX23l6, 243:4-15; EX2082, 1181.) Even if a POSA still
`
`
`
`
`
`
`
`
`would have Wanted to use BAC,
`
`
`
`
`
`
`
`
`
`
`the art provided a solution that would have
`
`
`
`
`
`
`
`
`
`
`
`addressed the NSAID/BAC interaction that underlies Lupin’s proffered motivation
`
`
`
`
`
`
`
`
`
`
`
`
`
`to use a solubilizer. Yanni teaches bromfenac derivatives Without free carboxyl
`
`
`
`
`
`
`groups, which would not
`
`
`
`
`
`
`
`
`
`
`interact with BAC and which have better ocular
`
`
`
`
`
`
`
`penetration and stability than bromfenac.
`
`
`
`
`
`
`
`
`(EX1007, 1:60-2:29; EX2082, 1186);
`
`
`
`
`
`
`
`
`Depuy Spine, 567 F.3d at 1326.
`
`
`
`
`
`
`
`
`
`
`
`Notwithstanding these clear teachings, Dr. Lawrence selectively relies on
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Ogawa Example 6, which reported a residual amount of bromfenac of 100.9%.
`
`
`
`
`
`
`
`
`
`
`
`
`
`(EX1005, 1111442-43.) But she ignores Ogawa Example 7, reporting an equally high
`
`
`
`
`12
`
`